Please assess the completion status of the following clinical trial:

Trial Title: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥40 years with moderate-severe COPD diagnosis according to the GOLD (The Global Initiative for Chronic Obstructive Lung Disease) strategy~* Patients who have symptomatic stable moderate to severe COPD diagnosis with post-bronchodilator FEV1/ Forced Vital Capacity (FVC) \<0.70, and FEV1 ≥30% and \<80% of predicted normal value at screening visit~* Current smokers or ex-smokers with a smoking history of at least 10 pack-years~* Patients who have no exacerbation within last 4 weeks~* Females patients with childbearing potential using effective birth control method~* Patients whose medication unchanged within least 4 weeks~* Patients who has a capability of communicate with investigator~* Patients who accept to comply with the requirements of the protocol~* Patients who signed written informed consent prior to participation~Exclusion Criteria:~* History of hypersensitivity to long acting beta-2 agonists or corticosteroids~* History of asthma or significant chronic respiratory diseases (e.g., interstitial lung diseases, significant bronchiectasis, etc.)~* Patients who had COPD exacerbation or lower respiratory track infections that required antibiotic, oral or parenteral corticosteroid treatment within 4 weeks prior to screening visit or during run-in period~* Use of immunosupresants or systemic corticosteroids within least 4 weeks~* History of severe cardiac arrhythmia or myocardial infarction within less than 6 months~* Significant or uncontrolled disease that may preclude participant from participating in the study~* Diognosis of cancer~* History of lung volume reduction operation~* Patients vaccinated with live attenuated vaccines within 2 weeks prior to screening visit or during run-in period~* Women patients who are pregnant or nursing~* History of allergic rhinitis and atopy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Salmeterol/Fluticasone Capsair® (Type: EXPERIMENTAL): Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
- Salmeterol/Fluticasone Diskus® (Type: ACTIVE_COMPARATOR): Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).